Agent Wolverton conducts deal on commercially reasonable efforts basis
By Devika Patel
Knoxville, Tenn., Nov. 5 – Hemostemix Inc. said it amended its C$4 million private placement of units. The deal is being conducted by Wolverton Securities Ltd. on a commercially reasonable efforts basis and priced on Oct. 8.
The company will now sell 6,153,847 units of one common share and one half-share warrant at C$0.65 per unit. Hemostemix previously planned to sell 5,714,286 units at C$0.70 per unit.
Each whole, two-year warrant is exercisable at C$1.25, an 83.82% premium to the Oct. 7 closing share price of C$0.68.
Proceeds will be used to accelerate phase 2 clinical trials for ACP 01 and for general working capital purposes.
The Toronto biotechnology company develops and commercializes blood-derived cell therapies for medical conditions.
| Issuer: | Hemostemix Inc.
|
| Issue: | Units of one common share and a half-share warrant
|
| Amount: | C$4 million
|
| Units: | 6,153,847
|
| Price: | C$0.65
|
| Warrants: | One half-share warrant per unit
|
| Warrant expiration: | Two years
|
| Warrant strike price: | C$1.25
|
| Agent: | Euro Pacific Canada Inc.
|
| Pricing date: | Oct. 8
|
| Revised: | Nov. 5
|
| Stock symbol: | TSX Venture: HEM
|
| Stock price: | C$0.68 at close Oct. 7
|
| Market capitalization: | C$39.38 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
